VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 183,974 shares, an increase of 76.3% from the June 30th total of 104,336 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 2,270,132 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

VYNE Therapeutics Stock Performance

NASDAQ VYNE opened at $28.32 on Friday. The firm has a market cap of $18.98 million, a PE ratio of -74.54 and a beta of 2.00. VYNE Therapeutics has a one year low of $14.03 and a one year high of $79.75. The firm’s fifty day moving average is $33.71 and its two-hundred day moving average is $31.49.

VYNE Therapeutics (NASDAQ:VYNE) last announced its earnings results on Friday, May 15th. The company reported ($4.00) earnings per share for the quarter, topping the consensus estimate of ($9.00) by $5.00. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.20 million.

VYNE Therapeutics Announces Dividend

The business also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were paid a dividend of $19.00 per share.

Institutional Trading of VYNE Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new position in shares of VYNE Therapeutics in the 4th quarter valued at approximately $46,000. Rangeley Capital LLC raised its stake in shares of VYNE Therapeutics by 18.1% during the first quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock worth $71,000 after purchasing an additional 18,064 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of VYNE Therapeutics during the third quarter worth $74,000. Geode Capital Management LLC lifted its holdings in shares of VYNE Therapeutics by 64.2% during the fourth quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock worth $131,000 after purchasing an additional 88,030 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in VYNE Therapeutics in the 4th quarter valued at $147,000. 83.78% of the stock is owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.